The choice of appropriate control group(s) is critical in cerebrospinal fluid (CSF) biomarker research in multiple sclerosis (MS). There is a lack of definitions and nomenclature of different control groups and a rationalized application of different control groups. We here propose consensus definitions and nomenclature for the following groups: healthy controls (HCs), spinal anesthesia subjects (SASs), inflammatory neurological disease controls (INDCs), peripheral inflammatory neurological disease controls (PINDCs), non-inflammatory neurological controls (NINDCs), symptomatic controls (SCs). Furthermore, we discuss the application of these control groups in specific study designs, such as for diagnostic biomarker studies, prognostic biomarker studies and therapeutic response studies. Application of these uniform definitions will lead to better comparability of biomarker studies and optimal use of available resources. This will lead to improved quality of CSF biomarker research in MS and related disorders.

Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis / C. Teunissen, T. Menge, A. Altintas, J.C. Álvarez-Cermeño, A. Bertolotto, F.S. Berven, L. Brundin, M. Comabella, M. Degn, F. Deisenhammer, F. Fazekas, D. Franciotta, J.L. Frederiksen, D. Galimberti, S. Gnanapavan, H. Hegen, B. Hemmer, R. Hintzen, S. Hughes, E. Iacobaeus, A.C. Kroksveen, J. Kuhle, J. Richert, H. Tumani, L.M. Villar, J. Drulovic, I. Dujmovic, M. Khalil, A. Bartos. - In: MULTIPLE SCLEROSIS. - ISSN 1352-4585. - 19:13(2013), pp. 1802-1809.

Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis

D. Galimberti;
2013

Abstract

The choice of appropriate control group(s) is critical in cerebrospinal fluid (CSF) biomarker research in multiple sclerosis (MS). There is a lack of definitions and nomenclature of different control groups and a rationalized application of different control groups. We here propose consensus definitions and nomenclature for the following groups: healthy controls (HCs), spinal anesthesia subjects (SASs), inflammatory neurological disease controls (INDCs), peripheral inflammatory neurological disease controls (PINDCs), non-inflammatory neurological controls (NINDCs), symptomatic controls (SCs). Furthermore, we discuss the application of these control groups in specific study designs, such as for diagnostic biomarker studies, prognostic biomarker studies and therapeutic response studies. Application of these uniform definitions will lead to better comparability of biomarker studies and optimal use of available resources. This will lead to improved quality of CSF biomarker research in MS and related disorders.
Biomarkers; cerebrospinal fluid; control groups; study design; Biomarkers; Consensus; Humans; Multiple Sclerosis; Patient Selection; Terminology as Topic; Control Groups; Research Design; Neurology; Neurology (clinical)
Settore MED/26 - Neurologia
2013
Article (author)
File in questo prodotto:
File Dimensione Formato  
19. Teunissen et al. 2013.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 810.7 kB
Formato Adobe PDF
810.7 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/514743
Citazioni
  • ???jsp.display-item.citation.pmc??? 41
  • Scopus 128
  • ???jsp.display-item.citation.isi??? 122
social impact